Alkermes Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00B56GVS15
USD
29.30
0.33 (1.14%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Exelixis, Inc.
Repligen Corp.
Neurocrine Biosciences, Inc.
United Therapeutics Corp.
Alkermes Plc
Intra-Cellular Therapies, Inc.
Jazz Pharmaceuticals Plc
Ionis Pharmaceuticals, Inc.
Catalent, Inc.
Roivant Sciences Ltd.
Karuna Therapeutics, Inc.
Why is Alkermes Plc ?
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Operating profit has grown by an annual rate 66.56%
3
The company declared negative results in Mar'25 after positive results in Dec'24
  • INVENTORY TURNOVER RATIO(HY) Lowest at 1.19 times
  • DEBTORS TURNOVER RATIO(HY) Lowest at 4.15 times
4
With ROE of 23.57%, it has a attractive valuation with a 3.54 Price to Book Value
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -1.26%, its profits have fallen by -26.4%
5
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -1.26% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Alkermes Plc should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Alkermes Plc for you?

Medium Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Alkermes Plc
-0.61%
0.56
35.66%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
5.32%
EBIT Growth (5y)
66.56%
EBIT to Interest (avg)
3.19
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.58
Sales to Capital Employed (avg)
0.98
Tax Ratio
15.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
21.80%
ROE (avg)
12.43%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.54
EV to EBIT
11.43
EV to EBITDA
10.67
EV to Capital Employed
7.05
EV to Sales
2.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
61.70%
ROE (Latest)
23.57%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 521 MM

RAW MATERIAL COST(Y)

Fallen by -3.27% (YoY

CASH AND EQV(HY)

Highest at USD 1,899.76 MM

DEBT-EQUITY RATIO (HY)

Lowest at -58.05 %

-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 1.19 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.15 times

Here's what is working for Alkermes Plc
Operating Cash Flow
Highest at USD 521 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv
Highest at USD 1,899.76 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -58.05 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -3.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 7.82 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Alkermes Plc
Inventory Turnover Ratio
Lowest at 1.19 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 4.15 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio